Charles Mathis, MD
Cardiovascular Disease · Elkhart, INNPI 1326042029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 848 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,489 and has fallen 65.8% since, to $852 in 2025.
Across 848 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Novartis$2K
- Amgen$970
- Boehringer Ingelheim$824
- Merck$791
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$657
- plus $6K from 35 others
Across 8 payments — averaging $6383.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$35K
- Astrazeneca UK Limited$16K
What the payments were for
- Food & beverage$13,063100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,074 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 378 | $430,693 |
| EntrestoSacubitril/Valsartan | 113 | $111,955 |
| XareltoRivaroxaban | 86 | $105,074 |
| JardianceEmpagliflozin | 51 | $55,211 |
| FarxigaDapagliflozin Propanediol | 54 | $46,662 |
| Repatha SureclickEvolocumab | 32 | $32,647 |
| VerquvoVericiguat | 33 | $31,530 |
| BrilintaTicagrelor | 24 | $13,827 |
| VascepaIcosapent Ethyl | 21 | $13,669 |
| Atorvastatin Calcium | 649 | $4,231 |
| Metoprolol Succinate | 346 | $4,188 |
| Amlodipine Besylate | 629 | $3,613 |
| Amiodarone Hcl | 110 | $3,192 |
| Carvedilol | 377 | $2,547 |
| ClopidogrelClopidogrel Bisulfate | 270 | $2,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $618 | $430,693378 claims |
| NovartisEntresto | $1,741 | $111,955113 claims |
| Johnson & JohnsonXarelto | $1,878 | $105,07486 claims |
| AstraZenecaFarxiga, Brilinta | $499 | $60,48878 claims |
| Boehringer IngelheimJardiance | $824 | $55,21151 claims |
| MerckVerquvo | $791 | $31,53033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Elkhart
- Wai LeeElkhart$321K
- Adil WaniElkhart$25K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.